about
Cardiovascular risk in rheumatoid arthritis: assessment, management and next stepsThe role of nailfoldcapillaroscopy in the assessment of internal organ involvement in Systemic Sclerosis: A critical review.Biologic drugs as analgesics for the management of osteoarthritis.A critical view on cardiovascular risk in systemic sclerosis.Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use.Symmetric Dimethylarginine Is Not Associated with Cumulative Inflammatory Load or Classical Cardiovascular Risk Factors in Rheumatoid Arthritis: A 6-Year Follow-Up Study.Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation.Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension.Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis.B-type natriuretic peptide in rheumatic diseases: a cardiac biomarker or a sophisticated acute phase reactant?Multimodality imaging and the emerging role of cardiac magnetic resonance in autoimmune myocarditis.The role of multimodality imaging in the evaluation of Takayasu arteritis.Biologic therapies and systemic bone loss in rheumatoid arthritis.Clinical outcome of ultrasound-guided steroid injections for chronic shoulder pain.Rheumatoid arthritis: an autoimmune disease with female preponderance and cardiovascular risk equivalent to diabetes mellitus: role of cardiovascular magnetic resonance.Cardiac and muscular involvement in idiopathic inflammatory myopathies: noninvasive diagnostic assessment and the role of cardiovascular and skeletal magnetic resonance imaging.Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment.Molecular and cellular pathways as treatment targets for biologic therapies in systemic sclerosis.Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis.Complementary role of cardiovascular imaging and laboratory indices in early detection of cardiovascular disease in systemic lupus erythematosus.Osteoarthritis pain has a significant neuropathic component: an exploratory in vivo patient model.Phenotyping Exercise Limitation in Systemic Sclerosis: The Use of Cardiopulmonary Exercise Testing.Genetic variations in the alanine-glyoxylate aminotransferase 2 (AGXT2) gene and dimethylarginines levels in rheumatoid arthritis.Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naïve patients with connective tissue diseases.In vivo microvascular and macrovascular endothelial function is not associated with circulating dimethylarginines in patients with rheumatoid arthritis: a prospective analysis of the DRACCO cohort.Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis.Associations between asymmetric dimethylarginine, homocysteine, and the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism (rs1801133) in rheumatoid arthritis.Lack of association between polymorphisms of thrombogenic genes and disease susceptibility in rheumatoid arthritis.Predictors and long-term outcome in Greek adults with juvenile idiopathic arthritis: a 17-year continuous follow-up study.Cardiac Tissue Characterization and Imaging in Autoimmune Rheumatic Diseases.Individualised exercise improves endothelial function in patients with rheumatoid arthritis.Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab.Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension.Limitations of the findings regarding the relationship between N-terminal pro-brain natriuretic peptide and systemic sclerosis-related pulmonary arterial hypertension: comment on the article by Allanore et al.The Role of Statins in Disease Modification and Cardiovascular Risk in Rheumatoid Arthritis.Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis.A case of sarcoidosis-associated pulmonary hypertension masquerading as chronic thromboembolic pulmonary hypertension.Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance.Symmetric dimethylarginine (SDMA) serum levels in rheumatoid arthritis: correlations with insulin resistance and disease activity scores.
P50
Q26744334-A6DC92D5-91F6-4436-84BA-004BCB349515Q30234119-FA0B0BD6-FECC-48EF-9A8C-14FDC51DB8A5Q30239849-C2EBFD88-730A-45F5-B9F2-55586FCD0F6CQ30249024-3EF59911-698C-44D5-9B9A-6CEF5F62242DQ30250316-DDFF5DF7-BB35-4E80-8556-9496C776C756Q36205262-3AF50196-8A53-4446-B606-AF3F6FEA65C2Q36276126-007BD9D9-432A-44A9-9DBF-2AF81B1FB958Q36396428-EACE2FE2-D173-4E81-86E5-E91443F757A0Q37524751-34A1C908-6CC3-47A7-9BC1-EA876E303B0FQ37981825-81EFC80C-4E14-4BD3-BF99-9FD20D3171CCQ37991823-2983F2F5-8AE7-4986-A2FC-CBA15A67C01FQ38012279-3B3E2778-7C4C-4D04-911B-02561B1B1F9EQ38037626-CE0FFBE1-1D6B-4EF5-9169-D90B9FB86B5CQ38094531-E8DBF947-895C-4D0C-BCC3-7F031B8EFC6EQ38132848-9C407BBD-9721-462A-ADBB-A04A9625CD84Q38183477-B0D35F12-CC59-46EF-BCA1-1469684BC9DFQ38215086-27857C81-29BF-43E8-9118-DEC96D77DA1CQ38220121-601EE3A9-596E-4E07-AE84-30B1586A68C1Q38409940-06DBE33D-2233-477B-97EA-CAC8574D2243Q38594078-F635A55A-1FED-44B6-BBFB-79003DFD23F9Q38968259-FFAA8D81-D089-43F5-8199-4C3761D43EF0Q39217490-3E4C40BE-197F-434D-9250-12E57520E8EEQ40145210-782E4E6A-C860-40A5-B9C4-6FAD9E032FDFQ40267428-EBD150D6-D0A1-4FAC-A272-4514D5C4551DQ40341391-73DFD551-03E0-41E0-9ADA-2834BB3403E1Q40760252-2C7DACA4-7D04-4882-95F7-8CD8F0ED4B89Q41097173-647BD389-B84C-4285-9E01-6F92BC9322B3Q41102153-670743D0-757D-4AEC-9213-1200FDA3EA76Q46121897-93808FA2-E319-448E-9714-B0A8FAB5DEB1Q47582373-54AE41E6-12DD-4A2D-B074-57FB6DADBC05Q47623515-87DB1F93-2FE2-458B-8BA8-349DA05460BFQ47886360-3019B117-822F-4E65-BB84-5C155C33D4E1Q48118262-544ABDC2-9550-4877-9439-C121FE29918BQ48377637-6251FC0C-B28A-46A0-B167-B1671E691DAAQ49160147-A8B97FE3-0CC5-4421-B84F-8E939AF680DCQ50192090-5A97C35E-7B74-43F5-AB2B-EBF08DA4C765Q51341574-E89BE643-3A66-4D78-9DC9-97EB3F84BD2AQ52656379-36E0D353-5BA0-48B6-B95F-FB24873DAAA6Q53221186-5705EE35-0602-4300-BE85-F7AC85B20012Q53583233-5B7FE446-B6A5-4B85-BAFB-A1024EBF14CD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Theodoros Dimitroulas
@ast
Theodoros Dimitroulas
@en
Theodoros Dimitroulas
@es
Theodoros Dimitroulas
@nl
Theodoros Dimitroulas
@sl
type
label
Theodoros Dimitroulas
@ast
Theodoros Dimitroulas
@en
Theodoros Dimitroulas
@es
Theodoros Dimitroulas
@nl
Theodoros Dimitroulas
@sl
prefLabel
Theodoros Dimitroulas
@ast
Theodoros Dimitroulas
@en
Theodoros Dimitroulas
@es
Theodoros Dimitroulas
@nl
Theodoros Dimitroulas
@sl
P106
P1153
9943768300
P21
P31
P496
0000-0002-0364-1642